Languages SpokenEnglish Prescribed MedicationsTriamcinolone Acetonide Ketoconazole Hydrocortisone Doxycycline Hyclate Betamethasone Dipropionate Mupirocin Imiquimod Fluocinonide Prednisone Clindamycin Research PublicationsApproximately 50% of Dermatologists in Johnson City, TN have available research publications Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. Erkki Lathouwers, Eric Y Wong, Kimberley Brown, Bryan Baugh, Anne Ghys, John Jezorwski, El Ghazi Mohsine, Erika Van Landuyt, Magda Opsomer, Sandra De Meyer, AMBER and EMERALD Study Groups AIDS research and human retroviruses 2019-10-21 Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Joseph J Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A Post, Stéphane De Wit, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, Kimberley Brown, Erika Van Landuyt, Magda Opsomer, EMERALD study group Antiviral research 2019-07-04 Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer, EMERALD study group The lancet. HIV 2017-10-06 Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Paul E Sax, David Wohl, Michael T Yin, Frank Post, Edwin DeJesus, Michael Saag, Anton Pozniak, Melanie Thompson, Daniel Podzamczer, Jean Michel Molina, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade-Villanueva, Gordon Crofoot, Joseph M Custodio, Andrew Plummer, Lijie Zhong, Huyen Cao, Hal Martin, Christian Callebaut, Andrew K Cheng, Marshall W Fordyce, Scott McCallister, GS-US-292-0104/0111 Study Team Lancet (London, England) 2015-04-15 A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. Naomi E Aronson, Glenn W Wortmann, William R Byrne, Robin S Howard, Wendy B Bernstein, Mary A Marovich, Mark E Polhemus, In-Kyu Yoon, Kelly A Hummer, Robert A Gasser, Charles N Oster, Paul M Benson PLoS neglected tropical diseases 2010-03-09 The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection. H-Y Huang, E S Daar, P E Sax, B Young, P Cook, P Benson, C Cohen, A Scribner, H Hu HIV medicine 2008-05 Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. Robert J Willard, Anelia M Jeffcoat, Paul M Benson, Douglas S Walsh Journal of the American Academy of Dermatology 2005-06 What is your diagnosis? Solitary mastocytoma. Amy Y Paul, Naomi Creel, Paul M Benson Cutis 2004-10 Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. T W Cheung, D T Jayaweera, D Pearce, P Benson, R Nahass, C Olson, G M Wool International journal of STD & AIDS 2000-10 Deep dermal granuloma annulare presenting as an eyelid tumor in a child, with review of pediatric eyelid lesions. S D Cronquist, M E Stashower, P M Benson Pediatric dermatology Payments From Medical Companies(These can include payments from pharmaceutical companies, medical device companies, and other companies.) Dr. Paul Benson, MD has received over $4,063 in payments from medical companies (22% more than the average Dermatologist in Johnson City, TN) - Over $3,940 in payments for Food and Beverage (22% more than the average Dermatologist in Johnson City, TN)
- Over $123 in payments for Education (25% more than the average Dermatologist in Johnson City, TN)
Amgen Inc. - $20.21 payment for Food and Beverage on 12/17/2024 Dermavant Sciences, Inc. - $15.33 payment for Food and Beverage on 12/11/2024 Novartis Pharmaceuticals Corporation - $17.92 payment for Food and Beverage on 11/25/2024 ABBVIE INC. - $16.07 payment for Food and Beverage on 11/05/2024 Regeneron Healthcare Solutions, Inc. - $4.05 payment for Food and Beverage on 10/25/2024 SUN PHARMACEUTICAL INDUSTRIES INC. - $20.94 payment for Food and Beverage on 10/15/2024 Amgen Inc. - $21.24 payment for Food and Beverage on 09/19/2024 E.R. Squibb & Sons, L.L.C. - $18.02 payment for Food and Beverage on 09/05/2024 Regeneron Healthcare Solutions, Inc. - $85.47 payment for Education on 08/02/2024 Regeneron Healthcare Solutions, Inc. - $20.11 payment for Food and Beverage on 07/17/2024
|